Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novo Nordisk A/S (ADR) (NVO)Hedge Funds Are Snapping Up

Page 1 of 2

After several tireless days we have finished crunching the numbers from the more than 700 13F filings issued by the successful hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Novo Nordisk A/S (ADR) (NYSE:NVO) .

Is Novo Nordisk A/S (ADR) (NYSE:NVO) a buy right now? Money managers are in an optimistic mood. The number of long hedge fund bets that are revealed through the 13F filings increased by 3 recently. NVOwas in 15 hedge funds’ portfolios at the end of September. There were 12 hedge funds in our database with NVO positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Bank of America Corp (NYSE:BAC), Taiwan Semiconductor Mfg. Co. Ltd. (ADR) (NYSE:TSM), and Altria Group Inc (NYSE:MO) to gather more data points.

Follow Novo Nordisk A S (NYSE:NVO)
Trade (NYSE:NVO) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

wavebreakmedia/Shutterstock.com

How have hedgies been trading Novo Nordisk A/S (ADR) (NYSE:NVO)?

At Q3’s end, a total of 15 of the hedge funds tracked by Insider Monkey held long positions in this stock, a gain of 25% from the previous quarter. Below, you can check out the change in hedge fund sentiment towards NVO over the last 5 quarters. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

10d
According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Jim Simons’ Renaissance Technologies holds the most valuable position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $609.4 million position in the stock, comprising 1.1% of its 13F portfolio. Sitting at the No. 2 spot is Fisher Asset Management, led by Ken Fisher, holding a $453.8 million position. Other peers that are bullish include Israel Englander’s Millennium Management, Tom Gayner’s Markel Gayner Asset Management and Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2
Loading...